Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer (El-porCEA)

• ClinicalTrials.gov Identifier: NCT01064375
• Recruitment Status: Unknown
• First Posted: February 8, 2010
• Last Update Posted: May 6, 2015
• Sponsor: Maria Liljefors
• Collaborators: Karolinska Institutet; Swedish Institute for Infectious Disease Control; Cyto Pulse Sciences, Inc.
• Information provided by (Responsible Party): Maria Liljefors, Karolinska University Hospital

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety and immunogenicity of a CEA DNA immunisation approach in patients with colorectal cancer. The DNA plasmid, tetwtCEA, encodes wild type human CEA fused to a tetanus toxoid T helper epitope. The vaccine will be delivered using an intradermal electroporation device, Derma Vax (Cyto Pulse Sciences). The following will be assessed:

• The efficiency of priming immunological responses to CEA by intradermal administration of CEA DNA in combination with electroporation.
• The efficiency of boosting immunological responses to CEA by intradermal administration of CEA DNA in combination with electroporation in subjects already vaccinated with CEA DNA.
• GM-CSF will be administered to half of the subjects primed with CEA DNA in combination with electroporation and any possible adjuvant effects of GM-CSF will be evaluated.

Condition or disease	Intervention/treatment	Phase
Colorectal Cancer	Biological: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope); Device: Derma Vax (electroporation device); Biological: GM-CSF; Drug: Cyclophosphamide	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer
• Study Start Date: December 2009
• Estimated Primary Completion Date: February 2017
• Estimated Study Completion Date: October 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: CEA DNA prime (cohort I); 5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.	Biological: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope); Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation; Other Names: GM-CSF; cyclophosphamide; Device: Derma Vax (electroporation device); Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration; Other Names: GM-CSF; cyclophosphamide; Drug: Cyclophosphamide; One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA; Other Name: Sendoxan
Experimental: CEA DNA boost (cohort II); 10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.	Biological: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope); Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation; Other Names: GM-CSF; cyclophosphamide; Device: Derma Vax (electroporation device); Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration; Other Names: GM-CSF; cyclophosphamide; Drug: Cyclophosphamide; One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA; Other Name: Sendoxan
Experimental: CEA DNA prime + GM-CSF (cohort III); 5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.	Biological: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope); Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation; Other Names: GM-CSF; cyclophosphamide; Device: Derma Vax (electroporation device); Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration; Other Names: GM-CSF; cyclophosphamide; Biological: GM-CSF; GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF; Other Name: cyclophosphamide; Drug: Cyclophosphamide; One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA; Other Name: Sendoxan

Outcome Measures

Primary Outcome Measures :

1. To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation. [ Time Frame: Within 72 weeks after immunisation ]

Secondary Outcome Measures :

1. To assess the efficiency of boosting immunological responses to CEA by intradermal administration of tetwtCEA DNA in combination with electroporation in subjects already vaccinated with CEA DNA [ Time Frame: Within 72 weeks after immunisation ]
2. To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF [ Time Frame: Within 72 weeks after immunsation ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histological confirmed AJCC stage II or III colorectal cancer
• Resection of the primary tumour without evidence of remaining macroscopic disease
• Allowable standard chemotherapy or radiotherapy in AJCC stage III completed minimum 2 months prior study entry
• Patients recruited from vaccination with CEA66 plasmid DNA must have completed trial at 18 months if immune response is proven or proven to be non-immune responders in two consecutive immunoassays.
• Age >18 years
• Karnofsky performance >80%
• Life expectancy of greater than 6 months
• Normal organ and marrow function
• Normal thyroid function as measured by serum T3, T4 and TSH
• Normal echocardiogram regarding arrhythmias (chronic or treated atrial fibrillation allowed)
• No concurrent treatment (chemotherapy or biological) may be planned during protocol treatment
• Women or men of reproductive potential must agree to use adequate contraception prior to study entry and for up to 3 months after the last injection
• Ability to understand and the willingness to sign an informed consent document

Exclusion Criteria:

• Immunotherapy or systemic corticosteroids within 8 weeks prior to entering the study
• Chemotherapy or radiotherapy within 2 months prior to entering the study
• Known hypersensitivity to GM-CSF
• Previous splenectomy or radiation therapy of the spleen
• Pregnancy or nursing
• HIV seropositivity
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic intracranial disease, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• History of severe neurological, cardiovascular, renal, hepatic, respiratory, bone marrow dysfunction, organ graft or autoimmune disease (treated or not)
• Concomitant medication with an anticoagulant (acetylsalicylic acid and low-molecular weight heparin in prophylactic dose allowed)
• Other malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
• Cardiac demand pacemakers or surgically implanted defibrillators.
• Patients that has any metal implants in the area of the injection, (e.g. shoulder implant in the upper arm or shoulder girdle)

Contacts and Locations

Locations

Sweden

Department of Oncology, Karolinska University Hospital

Stockholm, Sweden, 171 76

Sponsors and Collaborators

Maria Liljefors

Karolinska Institutet

Swedish Institute for Infectious Disease Control

Cyto Pulse Sciences, Inc.

Investigators

• Principal Investigator: Maria Liljefors, MD, PhD; Department of Oncology, Karolinska University Hospital/Institute

More Information

• Responsible Party: Maria Liljefors, MD, senior consultant, Karolinska University Hospital
• ClinicalTrials.gov Identifier: NCT01064375
• Other Study ID Numbers: El-porCEA; 2009-009863-75 ( EudraCT Number )
• First Posted: February 8, 2010
• Last Update Posted: May 6, 2015
• Last Verified: May 2015

Keywords provided by Maria Liljefors, Karolinska University Hospital:

DNA vaccine; Electroporation

Additional relevant MeSH terms:

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Cyclophosphamide; Molgramostim; Sargramostim; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists